The Importance of Early Diagnosis and Treatment in Spinal Muscular Atrophy Type 1
Author Information
Author(s): Edmar Zanoteli
Primary Institution: Universidade de São Paulo, Faculdade de Medicina, Departamento de Neurologia, São Paulo SP, Brazil
Hypothesis
Early initiation of disease-modifying therapies improves outcomes in patients with SMA-5q type 1.
Conclusion
The study emphasizes the efficacy of disease-modifying therapies in SMA-5q type 1 and the critical need for early diagnosis and treatment.
Supporting Evidence
- Early treatment leads to better outcomes in SMA-5q type 1 patients.
- Gene therapy showed more significant functional gains when started earlier.
- Patients with more advanced disease had less favorable outcomes.
- Stability of respiratory and bulbar functions was observed in most patients after treatment.
Takeaway
If kids with a certain disease get treatment early, they can do much better. This study shows that starting treatment quickly is really important.
Methodology
The study assessed the effects of nusinersen and gene therapy on motor, respiratory, and bulbar functions in patients with type 1 SMA-5q.
Potential Biases
Potential bias due to the observational nature of the study and the variability in treatment initiation times.
Limitations
The assessment of respiratory and bulbar functions is challenging in children due to the lack of specific scales and biomarkers.
Participant Demographics
Patients with type 1 spinal muscular atrophy, average age of treatment onset was 30.3 months for nusinersen and 15.2 months for gene therapy.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website